Potential role of metalloproteinase inhibitors from radiation-sterilized amnion dressings in the healing of venous leg ulcers

Molecular Medicine Reports

Volumn 6, Issue 4, 2012, Pages 723-728

  Litwiniuk, Małgorzata ^a   Bikowska, Barbara ^a   Niderla Bielińska, Justyna ^a   J́́ozwiak, Jarosław ^a   Kamiński, Artur ^a   Skopiński, Piotr ^a   Grzela, Tomasz ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Centrum Flebologii   (Poland)

Author keywords

Amniotic dressing; Matrix metalloproteinase; Metalloproteinase inhibitor; Venous leg ulcer

Indexed keywords

GELATINASE A; GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; AMNION; AMNION DRESSING; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LEG ULCER; MALE; MODIFIED BATES JENSEN QUESTIONNAIRE; PROTEIN MICROARRAY; QUESTIONNAIRE; WOUND DRESSING; WOUND HEALING; ZYMOGRAPHY;

AGED; AGED, 80 AND OVER; AMNION; BANDAGES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN ARRAY ANALYSIS; STERILIZATION; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VARICOSE ULCER; WOUND HEALING;

EID: 84865170731     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.983     Document Type: Article

References (21)

1. MacKenzie RK, Brown DA, Allan PL, Bradbury AW and Ruckley CV: A comparison of patients who developed venous leg ulceration before and after their 50th birthday. Eur J Vasc Endovasc Surg 26: 176-178, 2003. (Pubitemid 36927213)
2. Mustoe TA, O'Shaughnessy K and Kloeters O: Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg 117: S35-S41, 2006.
3. Litwiniuk M, Grzela T and Brawura-Biskupski-Samaha R: Clinical Immunology: Chronic inflammation in venous leg ulcer - problems and perspectives. Centr Eur J Immunol 34: 247-251, 2009.
4. Tauzin H, Humbert P, Viennet C, Saas P and Muret P: Human amniotic membrane in the management of chronic venous leg ulcers. Ann Dermatol Venereol 138: 572-579, 2011.
5. Litwiniuk M, Bikowska B, Niderla-Bieliñska J, Jóźwiak J, Kamiński A, Skopiński P and Grzela T: High molecular weight hyaluronan and stroma-embedded factors of radiation-sterilized amniotic membrane stimulate proliferation of HaCaT cell line in vitro. Centr Eur J Immunol 36: 205-211, 2011.
6. Jiang D, Liang J and Noble PW: Hyaluronan in tissue injury and repair. Ann Rev Cell Dev Biol 23: 435-461, 2007.
7. Wolbank S, Hildner F, Redl H, van Griensven M, Gabriel C and Hennerbichler S: Impact of human amniotic membrane preparation on release of angiogenic factors. J Tissue Eng Regen Med 3: 651-654, 2009.
8. Russo A, Bonci P and Bonci P: The effects of different preservation processes on the total protein and growth factor content in a new biological product developed from human amniotic membrane. Cell Tissue Bank 13: 353-361, 2012.
9. Tyszkiewicz JT, Uhrynowska-Tyszkiewicz IA, Kaminski A and Dziedzic-Goclawska A: Amnion allografts prepared in the Central Tissue Bank in Warsaw. Ann Transplant 4: 85-90, 1999.
10. Grzela T, Brawura-Biskupski-Samaha R, Jelenska MM and Szmidt J: Low molecular weight heparin treatment decreases MMP-9 plasma activity in patients with abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 35: 159-161, 2008. (Pubitemid 351163087)
11. Niknejad H, Peirovi H, Jorjani M, Ahmadiani A, Ghanavi J and Seifalian AM: Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater 15: 88-99, 2008. (Pubitemid 351955733)
12. Chem PL, Baum CL and Arpey CJ: Biologic dressings: current applications and limitations in dermatologic surgery. Dermatol Surg 35: 891-906, 2009.
13. Bjarnsholt T, Kirketerp-Moller, Jensen P, et al: Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen 16: 2-10, 2008.
14. Rayment EA, Upton Z and Shooter GK: Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br J Dermatol 158: 951-961, 2008. (Pubitemid 351521431)
15. Wysocki AB, Kusakabe AO, Chang S and Tuan TL: Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing. Wound Rep Reg 7: 154-165, 1999. (Pubitemid 29331919)
16. Saito S, Trovato MJ, You R, et al: Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg 34: 930-938, 2001. (Pubitemid 33661046)
17. Grzela T, Bikowska B and Litwiniuk M: Matrix metalloproteinases in aortic aneurysm - executors or executioners? In: Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture. Grundmann R (ed.). Intech Publ, pp25-54, 2011. Available from: http://www.intechopen.com/articles/ show/title/matrix-metalloproteinases-in-aorticaneurysm-executors-or- executioners-.
18. Fu X, Parks WC and Heinecke JW: Activation and silencing of matrix metalloproteinases. Semin Cell Dev Biol 19: 2-13, 2008. (Pubitemid 350235984)
19. Suzuki K, Nakayama H and Doi K: Kinetics of matrix metalloproteinases and their regulatory factors in mercuric chloride-induced tubulointerstitial fibrosis in Brown Norway rats. Exp Toxic Pathol 53: 337-343, 2001. (Pubitemid 33054899)
20. Duffy M: The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10: 39-49, 2004.
21. Bein K and Simons M: Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275: 32167-32173, 2000.